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Background: This study aimed for a collaborative evaluation of variability in the target volumes for glioblastoma,
determined and contoured by different radiotherapy (RT) facilities in Korea.
Methods: Fifteen panels of radiation oncologists from independent institutions contoured the gross target volumes
(GTVs) and clinical target volumes (CTVs) for 3-dimensional conformal RT or intensity-modulated RT on each simulation
CT images, after scrutinizing the enhanced T1-weighted and T2-weighted-fluid-attenuated inversion recovery MR images
of 9 different cases of glioblastoma. Degrees of contouring agreement were analyzed by the kappa statistics. Using the
algorithm of simultaneous truth and performance level estimation (STAPLE), GTVSTAPLE and CTVSTAPLE contours
were derived.
Results: Contour agreement was moderate (mean kappa 0.58) among the GTVs and was substantial (mean kappa
0.65) among the CTVs. However, each panels’ GTVs and modification of CTVs regarding anatomical structures
varied. Three-fourth of contoured panels’ CTVs encompassed the peritumoral areas of T2-high signal intensity
(T2-HSI). Nine of nine GTVSTAPLE encompased the surgical cavity and the T1-enhanced lesions. Eight of nine
CTVSTAPLE encompassed the peritumoral T2-HSI area. The median MARGIN90 and the median MARGIN95 were
1.4 cm and 1.5 cm, respectively.
Conclusions: Moderate to substantial agreement existed in target volumes for 3-dimensional or intensity-modulated
RT determined by radiation oncologists in Korea. According to the estimated consensus contours, the initial CTV
encompassed the GTV with margin less than 2.0 cm and the whole peritumoral areas of T2-HSI. The findings of our
study propose the need for further studies and modified guidelines.
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The prognosis of glioblastoma multiforme (GBM) has not
changed for the past 10 years since the European
Organization for Research and Treatment of Cancer
(EORTC) and National Cancer Institute of Canada (NCIC)
demonstrated a survival benefit with local radiotherapy (RT)
plus concomitant and adjuvant temozolomide (TMZ)
chemotherapy [1]. In the 1970s and 1980s, whole brain RT
was considered optimal. However, multiple series over
20 years including the Brain Tumor Cooperative Group 80–
01 randomized trial [2] have established local RT as the
current standard. Local RT, with smaller irradiated normal
brain volumes, produces less RT-induced neurotoxicity
[3, 4]. However, defining the optimal local RT treatment
volume in GBM remains controversial.
Local treatment volumes used for GBM have varied
among cooperative group trials and large-scale single insti-
tution studies, especially differing in margin from the gross
target volume (GTV) and inclusion of peritumoral edema.
The Radiation Therapy Oncology group (RTOG) recom-
mends that the initial clinical target volume (CTV) encom-
pass the entire T2-high signal intensity (T2-HSI; a mixture
of peritumoral edema and infiltrative tumor cells) defined
on post-operative magnetic resonance imaging (MRI) plus
2 cm, followed by a boost field defined as the residual T1-
enhancement and the surgical cavity plus 2.5 cm (per the
RTOG 0525 [5] and RTOG 0825 [6] trials). The rationale
for peritumoral edema inclusion is that histologically identi-
fied microscopic tumor cells have been found in these areas
[7, 8]. In contrast, EORTC recommends that the CTV
should encompass the T1-enhancement and surgical cavity
plus 2–3 cm without intentional inclusion of the T2-HSI
[1]. Reports that the majority of recurrences occur within
2 cm of the primary tumor [9–12] support the EORTC pro-
tocols. Furthermore, retrospective studies suggest that the
use of a margin less than 2 cm around the GTV or the
omission of intentional peritumoral edema inclusion doesTable 1 Clinical history of studied cases
Case Scenario Age /
Sex
Type o
surgery
1 Post-GTR M / 23 GTR
2 Extensive peritumoral edema M / 53 STBx
3 Multiplicity M / 56 PR
4 Near-falx location M / 31 GTR
5 Midline crossing F / 74 STBx
6 Combined with low grade glioma M / 42 PR
7 Infratentorial location M / 56 STR
8 Thalamic location M / 54 STBx
9 Localized ventricular seeding M / 62 STR
GTR gross total resection; STR subtotal resectionl; PR partial resection; STBx stereota
RT radiotherapy
aType of surgery was determined by the neurosurgeon and the postoperative MRI wnot alter the failure patterns of GBM [13–15]. Thus, no def-
inite consensus for the RT treatment volume in GBM has
been established so far.
For this reason, The Brain Tumor Committee of the
Korean Radiation Oncology Group (KROG) initiated the
KROG 13–18 study to evaluate current practice and vari-
ability of target volume delineation in GBM.
Methods and materials
Ethics
This study was performed with the approval of the Health
Institutional Review Board of Seoul National University
College of Medicine, Seoul, Korea.
Panels and contouring
Fifteen brain tumor expert radiation oncologists from 15
different institutions in Korea participated in the study.
They represented the 37 brain tumor expert radiation on-
cologists of the brain tumor committee of KROG. Six of
the 15 were from large scale institutions treating more
than 25 newly diagnosed GBM patients with RT per year.
Nine cases representing variable clinical scenarios of
GBM were chosen for the study. Clinical information
about tumor location, age/sex, extent of surgery, perform-
ance status, and pre-RT neurological symptoms was pro-
vided (Table 1). Patient history and image sets in ‘Digital
Imaging and Communications in Medicine’ formats were
provided to the panels. Axial pre- and post-operative MRI,
including T1-gadolinium enhanced (T1-GdE) and T2-
weighted-fluid-attenuated inversion recovery (T2-FLAIR)
images, as well as noncontrast-enhanced axial planning
computed tomography (CT) images taken in 3-mm slices
composed the image sets. Panels were encouraged to con-
tour the GTV and the initial CTV for all cases within each
institution’s planning system with a prerequisite of deliver-
ing 3-dimensional conformal RT or intensity-modulated
RT (IMRT), since all panels were surveyed to use one off
a
ECOG PS Pre-RT neurologic symptoms
Pre-op Post-op
1 0 None
3 1 Headache and dizziness
1 0 None
1 1 Mild headache
3 3 Mood change and helplessness
1 1 Dysphasia, dysarthria, and seizure
2 2 Headache and dizziness
1 1 Right lower extremity weakness
1 0 None
ctic biopsy; ECOG PS Eastern Cooperative Oncology Group Performance Status;
ithin 48 h
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operative MRI and planning CT images were recom-
mended for target contouring. The final contours were
returned for central analysis, and for statistical evaluation,
they were transferred into the Computational Environ-
ment for Radiotherapy Research, version 4.6 (Mathworks,
Natick, USA).
Panels’ contour agreement
The individual contours were all merged into a single scan.
The apparent agreement and kappa-corrected agreement
were used to measure consistency between panels [16].
1. Apparent agreement represents the overlap contour
obtained by average agreement probability of a voxel
selection by the radiation oncologists. The apparent
agreement probability of the ith voxel is calculated as:
pi ¼
Xm
j¼1rj
m
; i ¼ 1;…; n
rj = Rate by which the j
th panel selects the currentvoxel; in this case of inter-observer analysis, it is 0
or 1.
m =Number of panels.
n = Number of voxels selected by any of the panels
2. Generalized kappa statistics are an inter-observer
metric that corrects for agreement that could be ob-
tained by chance, and the kappa value is calculated as
follows [17, 18]:
Kappa ¼ Apparent Agreement −Chance Agreementð Þ
1−Chance Agreementð Þ
Chance Agreement = the expected agreement by
chance alone and is based on marginal totals:
Ym
j¼1
p rj ¼ 1
  þ
Ym
j¼1
p rj ¼ 0
 
The kappa values range between −1 and 1, with a
value of −1 representing complete disagreement, 0
representing no agreement above chance, and 1
representing perfect agreement. According to Landis
and Koch’s interpretation of strength of agreement,
kappa <0.00 is poor, 0.00 − 0.20 is slight, 0.21 − 0.40
is fair, 0.41 − 0.60 is moderate, 0.61 − 0.80 is
substantial, and 0.81 − 1.00 is near perfect
agreement [19].Estimated consensus contours; GTV/CTVSTAPLE
Consensus generation was done by maximum likelihood
estimation using the simultaneous truth and performance
level estimation (STAPLE) algorithm. Using the collection
of manually drawn contours provided by panels, the
STAPLE algorithm computes a probabilistic estimate ofthe ‘true contour’ that represents the desired tumor and
measures the performance of each segmentation [20]. The
probabilistic estimated consensus contours of GTV and
CTV of each case were generated in the form of GTVSTAPLE
and CTVSTAPLE, respectively, at a 95 % confidence level.
(1)Margin
To assess margin the from GTVSTAPLE to CTVSTAPLE,
MARGIN90 and MARGIN95 were used. MARGIN90
and MARGIN95 were the minimal margins needed to
cover at least 90 % and 95 % of the CTVSTAPLE
volume, respectively. The reason 100 % coverage
margin was not used was to allow for the effects of
variations in each physician’s policy of contouring
regarding clinical scenarios, irregularity of the
contour, anatomical modification of the CTVs
considering bony or ventricular structures, or
inclusion of peritumoral edema within the CTVs.
(2)Comparison with RTOG and EORTC
For comparison of the CTVSTAPLE and the CTV
based on RTOG/EORTC guidelines, CTVRTOG and
CTVEORTC were manually contoured in each case by
a single observer. Regarding the CTVEORTC
delineation, a 2.5-cm margin was utilized. The dice
similarity coefficient (DSC) index was used for
comparison of CTVRTOG and CTVEORTC overlap
with the CTVSTAPLE volume. DSC is calculated as
follows:
2  Volume of CTVSTAPLE ∩ CTVRTOG
EORTC
 h i
Volume of CTVSTAPLE þ Volume of CTVRTOG
EORTC
 
A DSC of 1 represents perfect overlap and thus
perfect agreement whereas the DSC is 0 if no
overlap exists [16].Results
Panels’ contour evaluation
All 15 participating panels contoured the GTV and CTV in
9 cases, resulting in a total of 135 GTVs and CTVs each.
GTV and CTV delineation reached moderate agreement
with mean kappa value of 0.58 and substantial agreement
with mean kappa value of 0.65, respectively. The quantita-
tive variability of the panels’ contours and the kappa values
of GTV and CTV in each case are shown in Table 2. Of the
135 GTVs, 100 % included the T1-enhancement in the
post-operative/biopsy MRI. If surgical resection was per-
formed, the resection margin was included in 100 % of the
contours whereas the whole surgical cavity, which indicates
the space of post-operative tissue defect with fluid collec-
tion created by surgical resection plus the surgical margin,
was included in only 81.1 % of the contours. Only 1 radi-
ation oncologist strictly confined the GTV to the resection
Table 2 Summary of panelist GTV and CTV volume statistics
GTV
Parameter Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Volume maximum (cm3) 134.50 123.02 123.06 189.49 284.10 278.52 77.11 146.65 190.20
Volume minimum (cm3) 22.34 21.88 34.22 21.61 80.85 18.50 5.13 16.79 10.44
Volume mean (cm3) 65.27 43.35 52.07 114.20 106.22 169.86 34.15 61.12 95.24
Volume SD (cm3) ±33.42 ±27.88 ±24.15 ±55.31 ±50.55 ±66.92 ±19.84 ±36.45 ±51.68
Volume SD / volume mean 0.51 0.64 0.46 0.48 0.48 0.39 0.58 0.60 0.54
Volume intersection (cm3) 11.59 10.63 19.68 0.84 57.85 13.21 2.34 12.16 6.79
Volume union (cm3) 175.36 135.03 162.01 238.47 304.28 327.70 101.84 157.29 256.10
Kappa value 0.58 0.59 0.65 0.51 0.74 0.61 0.49 0.53 0.48
Agreement level Moderate Moderate Substantial Moderate Substantial Substantial Moderate Moderate Moderate
CTV
Parameter Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Volume maximum (cm3) 486.35 485.32 531.45 419.49 817.83 564.00 247.17 388.33 636.09
Volume minimum (cm3) 61.96 181.74 83.18 194.91 176.76 259.26 64.22 80.23 150.10
Volume mean (cm3) 262.42 317.32 303.08 312.48 362.92 410.61 125.78 263.21 371.95
Volume SD (cm3) ±104.03 ±96.03 ±154.41 ±84.12 ±174.78 ±101.84 ±56.92 ±104.31 ±151.42
Volume SD / volume mean 0.40 0.30 0.51 0.27 0.48 0.25 0.45 0.40 0.41
Volume intersection (cm3) 25.53 134.41 53.97 46.67 145.25 217.43 31.73 71.49 104.90
Volume union (cm3) 572.74 591.32 609.61 534.51 880.28 693.43 311.87 510.41 724.87
Kappa value 0.63 0.71 0.55 0.68 0.64 0.74 0.62 0.62 0.65
Agreement level Moderate Substantial Moderate Substantial Substantial Substantial Substantial Substantial Substantial
GTV gross tumor volume; CTV clinical tumor volume; SD standard deviation
Fig. 1 a Case 1. RO #4 only included the resection margin for GTV (green
line) whereas RO #9 included both the resection margin and the resected
tumor bed (red line). b Case 4. RO #2 included both the resection margin
and the resected tumor bed (red line), in contrast to RO #4 (green line).
Abbreviation; GTV, gross target volume; RO, radiation oncologist
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included the whole surgical cavity in most cases (Fig. 1).
GTV included the T2-HSI in only 34.8 % of the panels’ con-
tours. In contrast, CTV included the whole T2-HSI in
74.8 % (Additional file 1: Table S1).
Evaluation of individual radiation oncologist’s modifi-
cation of CTVs after a simple margin expansion from
the GTVs, regarding potential anatomical barriers such
as the bony structure, falx, tentorium, and ventricular
system was also performed. Constraint regarding the
ventricular system means that no portion of the CTV
violates into the CSF space of the lateral ventricles,
which might occur if the CTV is not modified after sim-
ple margin expansion. All radiation oncologists were
found to constantly constrain the CTVs in proximity of
the bony structures. However, rates of constraining the
CTV in regards of the falx, tentorium, ventricular
system varied. The falx (80 %) and the tentorium (71 %)
were more strictly concerned compared to the ventricu-
lar system (34 %). Only 1 radiation oncologist strictly
concerned all 3 anatomical barriers throughout all 9
cases. In contrast, 1 radiation oncologist only concerned
those 3 barriers in only 22 % of the cases. The details
of results are shown elsewhere (Additional file 2:
Table S2).
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GTVSTAPLE included T1-enhancement in the post-
operative/biopsy MRI in all cases. In 6 surgically resected
cases GTVSTAPLE always encompassed not only the resec-
tion margin but also the whole surgical cavity. GTVSTAPLE
and CTVSTAPLE included the whole T2-HSI in 2 and 8
cases, respectively. The median MARGIN90 and MAR-
GIN95 were 1.4 cm (range, 1.0 − 2.5) and 1.5 cm (range,
1.2 − 2.8), respectively. T2-HSI inclusion rates and margin
statuses are shown in Table 3.
In the comparison between CTVSTAPLE and the guide-
line-based CTVs, the mean volume of the contour was the
smallest in CTVSTAPLE (329.76 cm
3) followed by CTVEORTC
(349.44 cm3 and CTVRTOG(458.65cm
3), although the dif-
ferences were not statistically significant. The mean DSC
was 0.77 (range, 0.52 − 0.85) between CTVSTAPLE and
CTVRTOG, and 0.78 (range, 0.69 − 0.86) between CTVSTA-
PLE and CTVEORTC (Table 4). In contrast to CTVRTOG,
which covers the T2-HSI plus an additional 2 cm,
CTVEORTC and CTVSTAPLE missed some areas of T2-HSI
in 4 and 1 of the 9 cases, respectively.
Discussion
RT with or without surgical resection is the standard of
GBM treatment. Therefore, a clear definition of the GTV
and CTV is necessary. Furthermore, the introduction of
TMZ has significantly prolonged the survival in these pa-
tients, and reports that specific molecular subgroups sur-
vive even longer [1, 21] has made the need for minimizing
unnecessary irradiation to the normal brain tissue more
urgent. Definite consensus guidelines for target delinea-
tion in GBM patients that address this need do not exist.
In this study, moderate and substantial agreements
among Korean radiation oncologists were observed for
GTV and CTV delineation, respectively. The levels of
agreement were comparable to the results of studiesTable 3 T2HSI inclusion rates, MARGIN90, and MARGIN95 of
each case
Case T2HSI MARGIN90
(cm)
MARGIN95
(cm)GTVSTAPLE CTVSTAPLE
Case 1 No Yes 1.6 1.8
Case 2 No Yes 1.9 2.2
Case 3 No Yes 2.5 2.8
Case 4 No Yes 1.4 1.6
Case 5 No No 1.1 1.2
Case 6 Yes Yes 1 1.2
Case 7 No Yes 1.2 1.4
Case 8 Yes Yes 1.4 1.5
Case 9 No Yes 1.9 2.3
Overall 22.20 % 93.30 % 1.4 (median) 1.5 (median)
T2-HSI T2-high signal intensity; STBx stereotactic biopsyinvolving different diseases that have utilized the same
methodology [22–25]. Small heterogeneity might not
result in significant differences in actually irradiated
volumes of the brain, but because more conformal radi-
ation techniques are available in current practice, accur-
ate target delineation is essential. First of all, accurate
delineation of the GTV after surgical resection is im-
portant. According to our study, most of the Korean ra-
diation oncologists tended to encompass the whole
surgical cavity, which includes both the space of post-
operative tissue defect with fluid collection and the re-
section margin, in the GTVs whereas only 1 radiation
oncologist strictly confined the GTVs to the resection
margin only in all cases. Fig. 1 shows the difference in 2
cases. Surrounding the brain tissue, there are several
dose limiting organs such as the brain stem, spinal cord,
optic apparatus, acoustic apparatus, hippocampus, etc.
In case 4, in contrast to case 1, the 2 displayed GTVs
differ largely in their volumes and the difference is likely
to increase when the CTVs are created by a margin ex-
pansion. Eventually, at the time of actual planning, the
optic apparatus are likely to limit the PTV coverage by
dose of 60 Gy or 61.2 Gy at the caudal aspect. Even in
case 1, although the volumes of the panels’ GTVs seem
not to differ largely, the final CTV or the PTV of the
GTV including the whole surgical cavity, if they are cre-
ated by margin expansion and not constrained to the
brain tissue, is likely to end up with a higher dose to the
patient’s scalp, resulting in either temporary or perman-
ent hair loss. Constraining the CTV strictly in proximity
of the potential anatomical barriers, such as the falx,
tentorium, and the ventricular space, is in a similar vein
with accurate GTV contouring. Since the space of post-
operative tissue defect with fluid collection do not har-
bor GBM tumor cells, future guidelines should propose
a more detailed definition of GTV in GBM. Further-
more, a strict quality assurance for CTV modification
regarding the anatomical barriers is necessary, especially
in a clinical trial setting.
Numerous data support proximity to the gross tumor as
the most important factor in predicting GBM recurrence
[9–12]. However, there are caveats to applying these results
of older studies to the modern era. Several modern MRI-
based studies [15] based on this principle utilized margins
less than 2 cm, such as 0.5 cm, 1.0 cm, or 1.5 cm. These
studies showed that the centrally failing pattern of GBM
does not change even with reduced margins. In our study,
the median MARGIN90 and MARGIN95 were 1.4 cm and
1.5 cm, respectively, which are less than 2 cm or 2.5 cm, as
utilized by the RTOG or EORTC. These findings appear to
reflect the disregarding of older RTOG/EORTC guidelines
by Korean radiation oncologists. The MARGIN90 and
MARGIN95 were 2.5 cm or more only in the case of multi-
centric GBM (case 3). Multiplicity at initial presentation
Table 4 Comparison between CTVSTAPLE, CTVRTOG, and CTVEORTC
Case CTVSTAPLE CTVRTOG CTVEORTC
Volume (cm3) Volume (cm3) DSC (with CTVSTAPLE) Volume (cm
3) DSC (with CTVSTAPLE)
Case 1 272.04 399.77 0.79 359.65 0.81
Case 2 340.18 447.84 0.84 403.87 0.86
Case 3 377.22 502.03 0.80 365.69 0.83
Case 4 347.00 455.77 0.79 443.21 0.77
Case 5 339.92 945.67 0.52 592.57 0.71
Case 6 424.29 440.22 0.85 304.26 0.79
Case 7 138.82 124.50 0.76 132.26 0.72
Case 8 309.10 251.25 0.77 177.93 0.69
Case 9 419.28 560.82 0.77 365.50 0.84
Mean value 329.76 458.65 0.77 349.44 0.78
DSC dice similarity coefficient
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compared to tumors presenting as solitary lesions. Demand
for highly aggressive therapy with larger RT treatment vol-
umes rather than relying on a single unified guideline may
be warranted for these patients. In cases where GTVSTAPLE
was defined as the T2-HSI (cases 6 and 8) as in the RTOG
trials, margins less than 1.5 cm were utilized, reflecting the
use of smaller margins than the RTOG guideline in contem-
porary practice even when T2-HSI is considered the gross
tumor. Reduction of treatment volumes based on the evi-
dence of failure patterns would yield smaller RT fields and
thus result in lesser neurologic morbidity in longer-
surviving patients. However, modern studies [13–15] have
not demonstrated the non-inferiority in local control rates.
Therefore, to justify the reduced margin below 2 cm, further
studies demonstrating equivalent local control with conven-
tional margins are necessary.
Another issue of controversy is whether it is necessary
to intentionally include peritumoral edema, which is often
simplified as T2-HSI on MRI, within the target volume.
Burger et al. [7] reported that the hypodense areas sur-
rounding the enhancing lesion on CT images contained
infiltrative tumor cells and infiltration of tumor cells may
extend even beyond the hypodense areas. Halperin et al.
[8] also reported that adding 3 cm to the hypodense area
is optimal for covering all infiltrative tumor cells. The
RTOG protocols mirror these findings. However, modern
series utilizing MRI [13–15] indicate that the omission of
intentional inclusion of peritumoral edema with reduced
margins does not change the failure pattern in GBM. In
our study, most panels’ GTVs and GTVSTAPLES did not
encompass the whole T2-HSI, suggesting that they tend to
overlook the RTOG recommendations. The two cases
(cases 6 and 8) in which the GTVSTAPLE encompassed the
whole T2-HSI, images showed mass-like T2-HSI lesions
indicating tumor mass rather than edema, whereas areas
of enhancement were not definite (Fig. 2). As someportion of GBM patients, up to 10–15 %, present with
non-enhancing tumors on MRI, future guidelines should
individualize the recommendation based on the initial
image findings of the tumor rather than unifying the def-
inition of GTV as the T1-enhancement or T2-HSI. In
contrast to the GTV, most of the panels’ CTVs and
CTVSTAPLES included the whole T2-HSI, indicating that
most Korean radiation oncologists do not ignore the pos-
sibility of malignant tumor cell existence in the T2-HSI.
On the other hand, additional margins around the T2-HSI
were not commonly observed in CTVSTAPLES. Eradicating
every malignant tumor cells is impossible, but at the same
time, totally neglecting the T2-HSI risks the possibility of
marginal recurrence. It would be difficult for the radiation
oncologist to ignore an obviously discemible T2-HSI.
Moreover, the volumes of CTVSTAPLE s encompassing the
whole T2-HSI actually did not differ significantly with
those of CTVEORTCS. One case (case 5) in which the
CTVSTAPLE missed areas of T2-HSI was a poorly per-
forming patient who underwent stereotactic biopsy
without tumor resection. The extensive infiltrative T2-
hyperintense and contrast-enhanced lesion involved
bilateral frontal lobes, both anterior horns of lateral
ventricles, the corpus callosum and bilateral basal gan-
glias combined with leptomeningeal seeding at the pon-
tomedullary junction (Additional file 3: Figure S1). The
volume of CTVRTOG was almost 3 times higher than
that of CTVSTAPLE. The low T2-HSI inclusion rate of
26.7 % in the panels’ CTVs for this case was probably a
result of the poor expected overall survival/disease con-
trol [26] and the high probability of radiation-related
morbidity [3, 4] in case of whole T2-HSI inclusion.
Panels may have been reluctant to administer aggressive
radical RT in such a case. As for target volumes for
other tumors, target volumes of GBM may be modified
based on individual clinical settings. In summary, a major-
ity of Korean radiation oncologists include the T2-HSI in
Fig. 2 a Pre-operative/biopsy gadolinium enhanced T1-weighted (T1-GdE) and T2-FLAIR images of case 6 and 8. b GTVSTAPLES (red) and CTVSTAPLES
(yellow) contoured on post-operative/biopsy MRIs of case 6 and 8
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GTV unless the T2-HSI lesion forms a mass like appear-
ance with no definitely enhancing lesion.
Several limitations exist in our study. One is that the
dose prescription scheme was not acquired. The RTOG
recommends 46 Gy in 23 fractions for the initial CTV
followed by a boost of 14 Gy in 7 fractions [5, 6], whereas
the EORTC recommends 60 Gy in 30 fractions for a single
field [1]. Individual institutions may adopt more variable
dose fractionation schemes in non-trial based practices
[19–21]. Whether the dose is prescribed to the GTV,
CTV, or the planning target volume with extra safety-
margins may also vary between panels. Lack of informa-
tion of the RT technique may also weaken our study asFig. 3 Depiction of the estimated consensus from the Korean Radiation On
b Tumors of mass forming T2-HSI without definite enhancement on T1-wethe use of IMRT for brain tumors is increasing. The in-
creasing use and importance of functional MRI techniques
like spectroscopy and diffuser tensor imaging, or 11C-me-
thionine positron emission tomography [27, 28] were also
not reflected in the current study. Nevertheless, the key
strengths of this study are that the evaluated number of
GTVs and CTVs, all contoured by brain tumor expert ra-
diation oncologists, is relatively high [22–25], and that
ours is the first report evaluating inter-observer variability
in GBM target delineation.
Conclusions
Although moderate and substantial agreement were ob-
served between Korean radiation oncologists for GTVcology Group 13–18 study. a Enhancing tumors on T1-weighted MRI.
ighted MRI
Wee et al. Radiation Oncology  (2015) 10:137 Page 8 of 9and CTV delineation, respectively, several variations were
present in delineating the GTV and constraining the CTV
in regards of anatomical barriers. Therefore, more detailed
guidelines for consistency of target volumes between radi-
ation oncologists are warranted. We found that most of
the practicing radiation oncologists tend to define the ini-
tial CTV by adding a < 2-cm margin around the GTV and
further encompass the remnant T2-HSI uncovered by the
margin (Fig. 3), based on modern evidence of failure pat-
terns. In conclusion, these findings of Korean pattern of
target volume delineation for GBM propose the need for
further studies and modified guidelines of target volume
delineation for future clinical trials. Further studies for
consensus formation evaluating disease control are ahead
from the brain tumor committee of the KROG.
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